Literature DB >> 35107075

Dupilumab, an emerging therapeutic choice for recalcitrant subepidermal autoimmune bullous diseases: a case series of three patients.

Xiuting Liu1, Jianchi Ma1, Xiaonan Qiu1, Dan Hong1, Liangchun Wang1, Zhenrui Shi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 35107075      PMCID： PMC8853335          DOI： 10.1684/ejd.2021.4190

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  6 in total

1.  Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology.

Authors:  C Feliciani; P Joly; M F Jonkman; G Zambruno; D Zillikens; D Ioannides; C Kowalewski; H Jedlickova; S Kárpáti; B Marinovic; D Mimouni; S Uzun; S Yayli; M Hertl; L Borradori
Journal:  Br J Dermatol       Date:  2015-04       Impact factor: 9.302

2.  Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid.

Authors:  Alex Kaye; Samantha C Gordon; Sandhya C Deverapalli; Min Ji Her; David Rosmarin
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

3.  Dupilumab for bullous pemphigoid with intractable pruritus.

Authors:  Jason S Seidman; Dawn Z Eichenfield; Charisse M Orme
Journal:  Dermatol Online J       Date:  2019-11-15

4.  Treatment of subepidermal immunobullous diseases.

Authors:  Donna A Culton; Luis A Diaz
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

5.  Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.

Authors:  Rana Abdat; Reid A Waldman; Valeria de Bedout; Annette Czernik; Michael Mcleod; Brett King; Samantha Gordon; Razzaque Ahmed; Anna Nichols; Marti Rothe; David Rosmarin
Journal:  J Am Acad Dermatol       Date:  2020-03-13       Impact factor: 11.527

6.  Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.

Authors:  S Morteza Seyed Jafari; Laurence Feldmeyer; Simon Bossart; Dagmar Simon; Christoph Schlapbach; Luca Borradori
Journal:  Front Immunol       Date:  2021-01-29       Impact factor: 7.561
  6 in total
  2 in total

Review 1.  Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?

Authors:  Roberto Russo; Niccolò Capurro; Emanuele Cozzani; Aurora Parodi
Journal:  J Clin Med       Date:  2022-06-12       Impact factor: 4.964

2.  Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.

Authors:  Peng Cao; Wenjing Xu; Litao Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.